News Elicera Therapeutics AB

Equities

ELIC

SE0015382080

Delayed Nasdaq Stockholm Other stock markets 11:18:25 2024-05-21 EDT			5-day change	1st Jan Change
0.984 ^SEK	-1.40%		+9.58%	-78.42%

03-28	Elicera Therapeutics AB Announces Director Changes	CI
03-06	Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Elicera Therapeutics publishes the annual report for 2023	04-16	AQ
Nomination committee proposes CMC specialist to Elicera's board of directors	03-28	AQ
Elicera Therapeutics AB Announces Director Changes	03-28	CI
Elicera Therapeutics changes Certified Adviser and Liquidity provider to Mangold Fondkommission AB	03-22	AQ
Elicera Therapeutics announces outcome in rights issue	03-11	AQ
BioStock: Elicera collaborates with US cancer centre to evaluate iTANK	03-07	AQ
Elicera enters agreement with prominent US Cancer Center to evaluate the use of iTANK in T-cell receptor therapies	03-06	AQ
Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies	03-06	CI
Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue	03-04	AQ
The subscription period in Elicera Therapeutics' rights issue of units starts today	02-23	AQ
Elicera Therapeutics publishes prospectus in connection with rights issue of units	02-21	AQ
BioStock: Full speed ahead for Elicera in 2024	02-19	AQ
Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024	02-16	AQ
Elicera Therapeutics AB to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1	02-16	CI
Elicera invites to investor meetings on February 28[th] and 29[th] 2024	02-16	AQ
BioStock: Elicera gets green light for CAR T clinical study	02-14	AQ
Elicera Therapeutics AB Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301	02-14	CI
Elicera Therapeutics AB (publ) Year-End Report 1 January - 31 December 2023	02-13	AQ
Elicera Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-13	CI
Elicera Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Elicera Therapeutics AB

Equities

ELIC

SE0015382080

Summary

Filters